跳至主要内容
临床试验/NCT04549493
NCT04549493已完成不适用

Effectiveness of Trauma Management Therapy and Prolonged Exposure Therapy for the Treatment of Post-Traumatic Stress Disorder in an Active Duty Sample: A Comparison Study

University of Central Florida2 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2020年2月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
134
试验地点
2
主要终点
Change from Baseline on the Clinician-Administered PTSD Scale for DSM-5

研究概览

简要总结

The purpose of this requirement is to identify an effective exposure psychotherapy paradigm for the treatment of Post-Traumatic Stress Disorder (PTSD) in active duty service members and veterans by comparing different exposure psychotherapy modalities. The long-term goal of exposure psychotherapy is to improve the mental health of U.S. service members and veterans with military-related PTSD. Recovery from PTSD will reduce the economic burden not only for those persons experiencing PTSD, but also for the health care system and society as a whole (Galovski & Lyons, 2004).

详细描述

This study will provide an evaluation of performance and suitability of the compressed versions of exposure psychotherapy to support the capability gap for the treatment of active duty service members and veterans with PTSD by comparing different exposure psychotherapy modalities. The overall objective of this study is to determine if compressed psychotherapy can be used as an effective alternative treatment for PTSD and to compare the impact of TMT and PE on social, familial, and occupational impairment. The primary objectives will be to compare 1) 3 week TMT with 12 week PE and 2) 3 week TMT with 2 week PE for the effectiveness of reducing PTSD symptoms in a gated approach or some other method to control for multiplicity. Outcomes will be determined based upon self-report, clinician ratings, as well as other aspects of psychopathology, and social/emotional functioning. The addition of the TMT group component will be assessed in particular to determine its impact on social, familial, and occupational impairment. Blood samples should be collected from participants at baseline and at the end of the treatment period in order to identify PTSD biomarkers, e.g. predictors of response, biological subtypes of PTSD, and therapeutic markers. Collection, storage, and transfer of the blood samples to DoD should be performed according to standardized protocols provided by the DoD. One or more site visits may occur in order to assess adherence to standardized protocols.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Active duty military personnel with a diagnoses of PTSD
  • Traumatic event must have occurred during military service
  • Military sexual trauma limited to attempted or completed sexual assault.

排除标准

  • Acute cardiac difficulties
  • Severe comorbid substance use disorders.
  • Diagnosis of schizophrenia or other psychotic disorders
  • Diagnosis of antisocial personality disorder
  • Moderate or severe traumatic brain injury (TBI)
  • Use of benzodiazepines

结局指标

主要结局

Change from Baseline on the Clinician-Administered PTSD Scale for DSM-5

时间窗: 6 months posttreatment

PTSD symptoms rating scale (severity and frequency) administered by blinded clinician

次要结局

  • Change from Baseline on the Traumatic Life Events Questionnaire (TLEQ)(6 months posttreatment)
  • Change from Baseline on the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)(6 months posttreatment)
  • Sleep actigraphy - change from baseline in total sleep time(6 months posttreatment)
  • Sleep actigraphy - change from baseline in sleep efficiency(6 months posttreatment)
  • Change from Baseline on the Posttraumatic Cognitions Inventory (PTCI)(6 months posttreatment)
  • Change from baseline on the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)(6 months posttreatment)
  • Change from baseline on the Generalized Anxiety Disorder-7 (GAD-7)(6 months posttreatment)
  • Change from baseline on the Patient Health Questionnaire-9 (PHQ-9)(6 months posttreatment)
  • Change from baseline on the Dimensions of Anger Reactions-5 (DAR-5)(6 months posttreatment)
  • Sleep actigraphy - change from baseline in sleep onset latency(6 months posttreatment)
  • Change from Baseline on the Trauma-Related Guilt Inventory (TRGI)(6 months posttreatment)
  • Change from Baseline on the Moral Injury Event Scale (MIES)(6 months posttreatment)
  • Change from baseline on the Quality of Life Scale (QOLS)(6 months posttreatment)
  • Change from baseline on the Connor-Davidson Resilience Scale (CD-RISC)(6 months posttreatment)
  • Change from baseline on the Clinical Global Impressions Scales (CGI)(6 months posttreatment)
  • Sleep actigraphy - change from baseline in wake minutes after sleep onset(6 months posttreatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验